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ABSTRACT Clinical immunity to malaria is associated with the acquisition of IgG
speciﬁc for members of the Plasmodium falciparum erythrocyte membrane protein 1
(PfEMP1) family of clonally variant antigens on the surface of infected erythrocytes
(IEs). The VAR2CSA subtype of PfEMP1 mediates IE binding in the placenta.
VAR2CSA-speciﬁc IgG is normally acquired only after exposure to placental parasites.
However, it was recently reported that men and children from Colombia often have
high levels of functional VAR2CSA-speciﬁc IgG. This potentially undermines the cur-
rent understanding of malaria immunity in pregnant women, and we thus con-
ducted a study to assess further the levels of VAR2CSA-speciﬁc IgG in pregnant and
nonpregnant Colombians. Plasma IgG against two full-length recombinant PfEMP1
proteins (one of the VAR2CSA type and one not) produced in baculovirus-
transfected insect cells was detected frequently among Colombian men, children,
and pregnant women with acute or previous malaria exposure. In contrast, IgG reac-
tivity to a homologous full-length VAR2CSA-type protein expressed in Chinese ham-
ster ovary (CHO) cells was low and infrequent among the Colombian plasma sam-
ples, as was reactivity to both corresponding native PfEMP1 proteins. Moreover,
human and rabbit antibodies speciﬁc for Plasmodium vivax Duffy-binding protein
(PvDBP), a protein with some homology to PfEMP1, did not react with VAR2CSA-
type recombinant or native proteins, although the mouse monoclonal and PvDBP-
speciﬁc antibody 3D10 was weakly reactive with recombinant proteins expressed in
baculovirus-transfected insect cells. Our data indicate that the previously reported
Colombian IgG reactivity to recombinant VAR2CSA is not malaria speciﬁc and that
the acquisition of VAR2CSA-speciﬁc IgG is restricted to pregnancy, in Colombia and
elsewhere.
KEYWORDS antibodies, baculovirus, CHO cells, Colombia, insect cells, malaria,
PfEMP1, Plasmodium falciparum, Plasmodium vivax, pregnancy, PvDBP, VAR2CSA, IgG,
adaptive immunity, humoral immunity, placental malaria, recombinant antigens
Malaria remains an important public health problem in large parts of the world. Anestimated 216 million malaria cases and 445,000 malaria-related deaths occurred
worldwide in 2016, most of them caused by Plasmodium falciparum in Africa (1).
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Outside Africa, Plasmodium vivax is responsible for about one-third of all malaria cases,
including most cases in Latin America (1). Colombia, with approximately 8 million
people living in areas where malaria is endemic, ranks third in the American continent
in terms of malaria transmission, with half a million cases being reported between 2007
and 2013 (1, 2).
In areas with stable P. falciparum transmission, children and pregnant women are at
a particularly high risk of malaria. This is because substantial protective immunity is
acquired during childhood and adolescence, making clinical episodes and severe cases
uncommon among adults (3). Malaria protection is mainly antibody mediated, and
antigens like P. falciparum erythrocyte membrane protein 1 (PfEMP1) expressed on the
infected erythrocyte (IE) surface are important targets (4). When women become
pregnant, particularly for the ﬁrst time, they become highly susceptible to malaria,
despite any clinical immunity acquired earlier in life (5). This appears related to the
ability of P. falciparum parasites to express a particular PfEMP1 subtype called VAR2CSA,
which is antigenically distinct from all other PfEMP1 proteins and facilitates the
selective accumulation of IEs in the placenta (6, 7). The expression of VAR2CSA is
generally assumed to be incompatible with parasite survival in nonpregnant individuals
(6, 8). Therefore, the acquisition of VAR2CSA-speciﬁc IgG is normally regarded as being
pregnancy restricted, despite a few reports of sporadic, low levels of VAR2CSA-speciﬁc
IgG among P. falciparum-exposed men, children, and nulligravidae (9–12).
The intensity of P. falciparum transmission in Colombia is low. Although at least 1
million women of reproductive age live in areas of the country where malaria is
endemic, malaria in pregnancy, including placental malaria, is uncommon (13–15). It
was therefore highly surprising when Gnidehou et al. reported a high prevalence of
VAR2CSA-speciﬁc IgG in Colombia, not only in women with a history of pregnancy but
also among nulligravidae, men, and children living in areas of the country where
malaria is endemic (16). That same group recently proposed that the high VAR2CSA
reactivity among Colombians might be related to cross-reactive antibodies induced by
the P. vivax Duffy-binding protein (PvDBP) (17), which has low-level homology to
PfEMP1.
The above-described ﬁndings from Colombia either point to a completely new and
unanticipated mode of acquisition of VAR2CSA-speciﬁc IgG or suggest that the current
understanding of immunity to placental malaria is incomplete. We therefore set out to
shed additional light on the prevalence and speciﬁcity of IgG recognizing VAR2CSA-
type PfEMP1 in Colombian populations.
RESULTS
IgG recognizing recombinant PfEMP1 proteins expressed in baculovirus-
transfected insect cells is prevalent in plasma from Colombian pregnant women,
men, and children. Signiﬁcant plasma levels of IgG speciﬁc for VAR2CSA-type PfEMP1
are usually restricted to P. falciparum-exposed women who are or have recently been
pregnant, and the levels generally correlate with parity among such women (18, 19).
However, Gnidehou et al. recently reported that this does not appear to be the case in
Colombia, as antibodies to recombinant VAR2CSA proteins did not depend on parity
and were equally prevalent among malaria-exposed women, men, and children (16). To
assess this surprising ﬁnding, we ﬁrst measured levels of FV2BIC-speciﬁc IgG in plasma
samples from different groups of Colombian donors (Fig. 1A). All the samples listed in
Table 1 were included in these enzyme-linked immunosorbent assays (ELISAs). In
agreement with data from the previous Colombian study, FV2BIC-speciﬁc IgG was
detected frequently in samples from all the malaria-exposed donor groups studied here
(set 1, set 2, and set 3b). With the exception of exposed men (set 1b; P  0.001) and
pregnant women (set 2c; P  0.001), the levels were not statistically signiﬁcantly
different from those observed in samples from nonpregnant Ghanaian women who
had been pregnant one or more times previously (set 5). Plasma levels of FV2BIC-speciﬁc
IgG were signiﬁcantly lower among unexposed Colombians (set 3a, set 4a, and set 4b;
enrollment samples) than among exposed Colombians (set 1 and set 2; P  0.001) but
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FIG 1 Antibody response to full-length recombinant PfEMP1 proteins produced in baculovirus-transfected insect cells. (A to D) IgG levels
against a recombinant, full-length VAR2CSA-type PfEMP1 protein (FV2BIC) (A and B) and a full-length non-VAR2CSA-type PfEMP1 protein
(FV6BIC) (C and D) produced in baculovirus-transfected insect cells were determined by an ELISA. Individual data for all samples sets are
(Continued on next page)
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were still signiﬁcantly higher than the levels among negative-control donors from
Denmark (set 6; P  0.001) (Fig. 1A). As reported previously by Gnidehou et al. (16),
levels among the pregnant Colombian women studied did not differ between primi-
gravidae and multigravidae (Fig. 1B). Although the FV2BIC-speciﬁc IgG levels also did
not differ signiﬁcantly between primigravidae and multigravidae among the Ghanaian
women included here, such a difference was evident in the much larger sample set (18)
from which the samples in set 5 were randomly drawn.
We also measured plasma levels of IgG speciﬁc for another full-length recombinant
protein (FV6BIC), expressed as FV2BIC but representing a PfEMP1 antigen that is com-
monly recognized by plasma IgG from naturally exposed African donors. The expression
of this PfEMP1 antigen is not restricted to parasites infecting pregnant women (18). The
results (Fig. 1C and D) were strikingly similar to those obtained with FV2BIC. Further-
more, there was a signiﬁcant and strong positive correlation between the FV2BIC and
FV6BIC data among the Colombian samples (Fig. 1E) that was not observed in the
corresponding data from Ghana (Fig. 1F). Taken together, these ﬁndings are in agree-
ment with data from the previous study by Gnidehou et al. (16) and extend the
surprisingly high and prevalent plasma antibody reactivity to recombinant VAR2CSA-
type PfEMP1 among Colombian donors to comprise reactivity to a recombinant PfEMP1
protein (FV6BIC) that is not restricted to pregnancy (18, 20).
IgG recognizing native VAR2CSA-type PfEMP1 expressed on the surface of P.
falciparum-infected erythrocytes is rare in plasma from Colombian individuals. To
substantiate the above-described ﬁndings, we next measured plasma IgG reactivity
against erythrocytes infected with P. falciparum parasites selected in vitro to express the
PfEMP1 antigens represented by the recombinant proteins used in the ELISAs described
above. Subsets of the plasma samples in the various sets, selected to include those with
the highest FV2BIC reactivity by ELISAs, were used, as speciﬁed in Table 1. Between 7%
(children and men) and 20% (pregnant women) of the samples from Colombia had IgG
levels to IT4VAR04 (the native counterpart of FV2) above the negative cutoff level (Fig.
2A). Sixty-three percent of the nonpregnant Ghanaian women had levels of IT4VAR04-
speciﬁc IgG above the cutoff. Between 61% (children) and 84% (pregnant women) of
samples had levels of IgG recognizing IEs expressing HB3VAR06 (the native counterpart
of FV6) above the cutoff (Fig. 2B). Antibody levels to the corresponding native and
recombinant antigens did not correlate signiﬁcantly, regardless of whether all the
Colombian samples (Fig. 2C and E) or only the samples from the Colombian pregnant
women (Fig. 2D and F) were considered. In contrast, plasma from Ghanaian women
with a pregnancy history reacted strongly with both IT4VAR04 and HB3VAR06 (Fig. 2A
and B; see also Fig. S1A and S2A in the supplemental material). Furthermore, levels of
IgG recognizing the corresponding native and recombinant versions of either antigen
were positively and signiﬁcantly correlated among the samples from the Ghanaian
women (Fig. 2G and H). These results suggest that the plasma samples from the
Colombian donors recognized a component(s) that is present in both recombinant
PfEMP1 antigens expressed in baculovirus-transfected insect cells but is not present in
the corresponding native antigens and therefore is possibly not related to malaria
exposure.
IgG recognizing recombinant VAR2CSA-type PfEMP1 expressed in CHO cells is
rare in plasma from nonpregnant Colombian individuals. To assess the hypothesis
that the reactivity to FV2BIC among the Colombian donors was not P. falciparum
speciﬁc, we generated another recombinant full-length PfEMP1 antigen containing the
same amino acid sequence as that of FV2BIC but expressed in a mammalian cell line
FIG 1 Legend (Continued)
described in Table 1 (A and C). Individual data for samples in set 2c (Colombian pregnant women) and set 5 (Ghanaian women) were sorted
by parity (primigravid [Primi] and multigravid [Multi]) (B and D). Medians and interquartile ranges are also shown. (E and F) Correlation (rs)
between IgG levels speciﬁc for FV2BIC and FV6BIC in Colombian (set 1 and set 2) (E) and Ghanaian (set 5) (F) samples. The statistical signiﬁcance
levels of the correlations are also shown. In all panels, the values are expressed in arbitrary units (AU) (see Materials and Methods for details),
and dashed lines indicate the negative cutoff values (mean levels plus 2 SD for Danish controls).
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FIG 2 Antibody responses to native PfEMP1 and recombinant PfEMP1 proteins produced in baculovirus-
transfected insect cells. (A and B) Levels of IgG speciﬁc for native VAR2CSA-type (IT4VAR04) PfEMP1 (A)
and native non-VAR2CSA-type (HB3VAR06) PfEMP1 (B) expressed on the surface of IEs and measured by
(Continued on next page)
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(Chinese hamster ovary [CHO]) rather than in insect cells. Levels of IgG to this protein
(FV2CHO) were generally low among all groups of Colombian donors (Fig. 3A). The
differences between the Colombian and Ghanaian donors were statistically signiﬁcant
for all the groups except sets 2a and 2b, despite the fact that the Ghanaian women
were not pregnant and therefore were not expected to have high levels of VAR2CSA-
speciﬁc IgG, due to the rapid decline of these antibodies postpartum (21, 22). FV2CHO-
speciﬁc IgG levels were weakly and positively correlated with IgG levels to FV2BIC (Fig.
3B), in contrast to the plasma samples from the Ghanaian donors, where IgG levels to
the these antigens were very strongly correlated (Fig. 3C). Antibody levels to FV2CHO
and the corresponding native protein did not correlate signiﬁcantly when all the
samples from Colombia were considered (Fig. 3D). When the samples were further
analyzed according to donor type (see Fig. S3 in the supplemental material), a weak
positive correlation between FV2CHO- and IT4VAR04-speciﬁc IgG was observed in the
samples from the Colombian pregnant women (set 2c) but not in the samples from
children (set 1a and set 2a) or men (set 1b and set 2b). This suggests that some of the
Colombian women had been exposed to VAR2CSA-positive IEs during their pregnancy.
These ﬁndings suggest that most of the apparently VAR2CSA-speciﬁc IgG in the
Colombian plasma samples actually recognized so-far-unidentiﬁed epitopes present
only in the recombinant proteins produced in insect cells. In contrast, levels of IgG
reacting with FV2BIC, FV2CHO, and the corresponding native protein on IEs were
positively correlated among the samples from Ghana (Fig. 2G and H and 3C), indicating
that IgG recognizing these epitopes is not induced in Ghana.
IgG reactivity to FV2BIC in Colombian plasma samples cannot be depleted in
vitro by preexposure to FV2CHO. We next sought to provide additional evidence
that the reactivity to FV2BIC among the Colombian donors was indeed directed
toward non-PfEMP1-speciﬁc epitopes that are present in recombinant proteins
expressed in baculovirus-transfected insect cells but absent from proteins ex-
pressed in CHO cells and absent in native PfEMP1 proteins. To this end, we
sequentially measured IgG reactivity against FV2BIC, FV2CHO, and FV6BIC in plasma
pools transferred from one ELISA plate to the next (Fig. 4). When pools were
depleted in this way of IgG reacting with FV2BIC (Fig. 4A, D, G, and J), FV2CHO (Fig.
4B, E, H, and K), or FV6BIC (Fig. 4C, F, I, and L), respectively, reactivities in the plasma
pools from Colombian (Fig. 4G to I) and Ghanaian (Fig. 4J to L) women were
signiﬁcantly reduced from the ﬁrst ELISA to the second ELISA. In marked contrast,
the reactivities to FV2BIC in pools from Colombian unexposed donors (Fig. 4E) and
Colombian pregnant women (Fig. 4H) were unaffected by two rounds of FV2CHO-
speciﬁc IgG depletion, whereas essentially no reactivity was left in the Ghanaian
pool treated in this way (Fig. 4K). Conversely, reactivity to FV2BIC was essentially
absent from each of the two initially FV2BIC-reactive Colombian pools after two
FV6BIC ELISAs (Fig. 4F and I), whereas the FV2BIC reactivity in the Ghanaian pool was largely
unaffected (Fig. 4L). Taken together, these depletion experiments strengthen the hypoth-
esis that the widespread Colombian IgG reactivity to recombinant PfEMP1 antigens
produced in baculovirus-transfected insect cells is not P. falciparum speciﬁc.
Experimental exposure to P. vivax-infected mosquitoes does not induce IgG
speciﬁc for VAR2CSA-type PfEMP1. It has been proposed that exposure to P. vivax
can elicit IgG responses that cross-react with VAR2CSA-type PfEMP1 (16, 23). This
FIG 2 Legend (Continued)
ﬂow cytometry. (C and D) Correlation (rs) between IgG levels speciﬁc for recombinant (FV2BIC) and native
(IT4VAR04) VAR2CSA-type PfEMP1 in samples from Colombian exposed, healthy, and naturally infected
individuals (set 1 and set 2) (C) or from Colombian pregnant women only (D). (E and F) Correlation (rs)
between IgG levels speciﬁc for recombinant (FV6BIC) and native (HB3VAR06) non-VAR2CSA-type PfEMP1
in Colombian samples (set 1 and set 2) (E) or in samples from Colombian pregnant women only (set 2c)
(F). (G and H) Correlation (rs) between IgG levels speciﬁc for recombinant (FV2BIC) and native (IT4VAR04)
VAR2CSA-type PfEMP1 (G) and between IgG levels speciﬁc for recombinant (FV6BIC) and native
(HB3VAR06) non-VAR2CSA-type PfEMP1 (H) in samples from Ghanaian women. The statistical signiﬁcance
levels of the correlations are also shown. The panel layout is the same as in Fig. 1.
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hypothesis is consistent with both the pregnancy restriction of VAR2CSA reactivity in
Africa (where P. vivax is rare and not an important cause of placental malaria [24]) and
the apparent absence of such restriction in Colombia (where P. vivax is common). Those
same authors proposed that the cross-reactivity is mediated by PvDBP (17). We
therefore measured levels of FV2BIC-, FV2CHO-, FV6BIC-, and PvDBP-speciﬁc IgG in plasma
samples from 16 adults participating in a controlled human P. vivax malaria infection
FIG 3 Antibody responses to native PfEMP1 and recombinant PfEMP1 proteins produced in insect or CHO cells. IgG levels against recombinant
(FV2BIC and FV2CHO) and the corresponding native (IT4VAR04) VAR2CSA-type PfEMP1 proteins were determined by an ELISA (recombinant
proteins) or ﬂow cytometry (native protein). (A) Individual FV2CHO-speciﬁc IgG levels in all samples (sample sets 1 to 6). (B and C) Correlation (rs)
between IgG levels speciﬁc for FV2BIC and FV2CHO in Colombian (set 1 and set 2) (B) and Ghanaian (set 5) (C) samples. (D) Correlation (rs) between
IgG levels speciﬁc for FV2CHO and the corresponding native VAR2CSA-type protein in Colombian samples (set 1 and set 2). The panel layout is
the same as in Fig. 1.
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(PvCHMI) trial (set 3) (25). In all cases, the data were normalized by subtraction of the
background reactivity at enrollment to reveal only the IgG reactivity induced in
response to P. vivax infection. After normalization, no reactivity was observed at the
time of patency (Fig. 5), meaning that antibodies did not develop after experimental
FIG 4 Antibody levels to recombinant PfEMP1 full-length proteins in plasma pools tested in serial ELISAs. Shown are IgG levels in pooled plasma from Danish
control donors (set 6) (A to C), unexposed Colombians (sets 3a, 4a, and 4b) (D to F), Colombian pregnant women (set 2c) (G to I), and Ghanaian women
(set 5) (J to L). In each of the three ELISA series (series 1 [A, D, G, and J], series 2 [B, E, H, and K], and series 3 [C, F, I, and L]), the plasma pools were transferred
directly from the ﬁrst to the second ELISA plates and then from the second to the third ELISA plates. In series 1, an FV2BIC-speciﬁc ELISA was used for all
three consecutive measurements. In series 2, the ﬁrst two measurements were FV2CHO speciﬁc, while the third ELISA was FV2BIC speciﬁc. In series 3, the ﬁrst
two measurements were FV6BIC speciﬁc, while the third ELISA was FV2BIC speciﬁc. To allow comparison of data among panels, levels are expressed as how
many folds higher they were than the levels in the corresponding control ELISAs without antigen (ﬁrst and second ELISAs) and shown as means and SD.
*, P  0.05; ***, P  0.001 (using Kruskal-Wallis test followed by Dunn’s multiple-comparison analysis).
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FIG 5 Induction of IgG responses to recombinant PfEMP1 proteins following experimental exposure to P. vivax-infected
mosquitoes. Shown are plasma levels of IgG in samples from set 3 (open symbols) at the time of microscopically detectable
parasitemia (patency) and 45 days after infection (follow-up) and in samples from set 4 (closed symbols) following seven
rounds of immunization by infected mosquito bites (Post_imm) and 6 months after PvCHMI infection (Post_CHMI). Levels
of IgG speciﬁc for FV2BIC (A), FV2CHO (B), FV6BIC (C), and PvDBP (D) are shown. Data from individual donors are linked by
lines. The panel layout is otherwise the same as in Fig. 1.
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infection. One unexposed donor showed a weak positive response to FV6BIC (Fig. 5C),
and one exposed donor showed a strong positive response to PvDBP (Fig. 5D) at the
time of follow-up after experimental P. vivax infection. Nevertheless, several of the
volunteers seroconverted for many other P. vivax antigens in response to the experi-
mental infection (25, 26). Similar results using FV2BIC, FV2CHO, FV6BIC, and PvDBP were
obtained with samples from 17 adult volunteers without previous malaria exposure but
experimentally immunized by repeated exposure to irradiated (Duffy-positive [Fy]
donors [set 4a]) or nonirradiated (Duffy-negative [Fy] donors [set 4c]) P. vivax-infected
mosquitoes (27) (Fig. 5). Taken together, these data indicate that exposure to P. vivax
parasites does not induce IgG that robustly recognizes PfEMP1 in general or VAR2CSA-
type PfEMP1 in particular.
PvDBP-speciﬁc antibodies do not recognize PfEMP1. To investigate further
whether the Colombian plasma IgG reactivity with recombinant PfEMP1 proteins
could be due to cross-reactivity with IgG induced by PvDBP, we tested the ability
of PvDBP-speciﬁc antibodies raised in different species to recognize recombinant
and native PfEMP1. We ﬁrst tested the reactivity of the mouse monoclonal antibody
3D10 (28), which was previously reported to cross-react with VAR2CSA-type PfEMP1
(17). This monoclonal antibody in fact showed low reactivity with FV2BIC (endpoint
titer of 0.08 g/ml using mouse IgG as a reference) (Fig. 6A) but reacted only very
weakly with FV2CHO (endpoint titer of 10 g/ml) (Fig. 6C) and not with the
corresponding native PfEMP1 protein IT4VAR04 (see Fig. S1B to S1D in the supple-
mental material). The 3D10 antibody reacted weakly with FV6BIC (Fig. 6E), much to
the same extent as it reacted with FV2BIC (endpoint titer of 0.08 g/ml), but 3D10
did not label the native counterpart of FV6, HB3VAR06 (Fig. S2 B). It thus appears
that 3D10, in addition to its speciﬁcity for PvDBP (28), also has some reactivity with
recombinant proteins expressed in baculovirus-transfected insect cells. In marked
contrast, we observed no reactivity of the PvDBP-speciﬁc human monoclonal
antibody DBL10, generated from memory B cells of a volunteer in a recent PvDBP
vaccination trial (29; Thomas Rawlinson, unpublished data), with any of the recom-
binant full-length PfEMP1 proteins (Fig. 6A, C, and E) or with IT4VAR04-positive (Fig.
S1E) or HB3VAR06-positive (Fig. S2C) IEs. A corresponding lack of reactivity was
observed with an antiserum from PvDBP-immunized rabbits (30) (Fig. 6B, D, and F
and Fig. S1F and S2D). All the following PvDBP-speciﬁc antibody reagents showed
high reactivity with a recombinant PvDBP expressed in Escherichia coli (28): rabbit
anti-PvDBP serum (optical density [OD] of 0.48  0.10 at a 1:2,560 dilution), DBL10
(OD of 2.88  0.16 at 0.08 g/ml), and 3D10 (OD of 1.86  0.09 at 0.08 g/ml).
Taken as a whole, data from these experiments indicate that immunization with
PvDBP does not generally induce antibodies that cross-react with PfEMP1.
DISCUSSION
VAR2CSA-type PfEMP1 proteins mediate the selective accumulation of IEs infected
with P. falciparum in the placenta (19, 31–33). This can have serious consequences for
a pregnant woman as well as for her unborn child (fetus), because the ensuing
inﬂammation compromises the transfer of nutrients, antibodies, and waste products
between mother and fetus (reviewed in reference 7). Placental malaria is an important
component of the unacceptable infection burden imposed by P. falciparum on people
living in the tropics, in particular sub-Saharan Africa. More than 50 million pregnancies
each year are at risk of placental malaria (34), and 100,000 infants die because of
placental malaria (5). Following exposure to VAR2CSA-type PfEMP1 during pregnancy,
women acquire substantial IgG-mediated protection against placental malaria, which is
therefore markedly concentrated among women of low parity, in particular primigrav-
idae (reviewed in reference 6). This fact, and the identiﬁcation of the so-called minimal
binding domain in VAR2CSA-type PfEMP1 that binds to its cognate receptor, oncofetal
chondroitin sulfate, has raised hopes that it may be possible to vaccinate against
placental malaria (35–38). Clinical phase Ia/b trials of such vaccines are currently in
progress (39, 40).
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FIG 6 Reactivity of PvDBP-speciﬁc IgG with recombinant PfEMP1 proteins. Shown are ELISA reactivities of PvDBP-speciﬁc human
(DBL10) and mouse (3D10) monoclonal antibodies (mAb) (A, C, and E) and PvDBP-speciﬁc rabbit antiserum (B, D, and F) with the
recombinant full-length PfEMP1 proteins FV2BIC (A and B), FV2CHO (C and D), and FV6BIC (E and F). (A, C, and E) Reactivities of irrelevant
(Continued on next page)
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A few years back, Gnidehou et al. (16) reported widespread IgG reactivity to
VAR2CSA-type PfEMP1 in Colombian children and adults of both sexes and in women
of all parities. Those ﬁndings are in marked contrast to essentially all other studies,
mostly from Africa, documenting that high levels of VAR2CSA-speciﬁc IgG are restricted
to pregnant women, that levels correlate with parity, and that VAR2CSA-speciﬁc IgG
declines to low levels soon after delivery (reviewed in reference 6). Those authors
speculated that the reason for their unanticipated ﬁndings might be the presence of
another malaria parasite, P. vivax, which is essentially absent from most of Africa. More
speciﬁcally, they recently proposed that VAR2CSA-speciﬁc IgG might be induced by
cross-reactive epitopes in the P. vivax antigen PvDBP (17). The studies by Gnidehou et
al. (16, 17) thus point to a completely new and unanticipated mode of acquisition and
maintenance of VAR2CSA-speciﬁc IgG, although BLAST analysis of IT4VAR04 showed
only low sequence homology (26%) with PvDBP (PVP01_0623800.1-p1). The ﬁndings
from Colombia also raise questions regarding the rationale that underpins current
efforts to develop VAR2CSA-based vaccines to protect young women against placental
malaria (reviewed in reference 41). We therefore sought to examine in detail the
unexpected results from the Colombian studies, using both recombinant and native
VAR2CSA proteins. We used full-length recombinant proteins rather than the smaller
constructs (DBL5, DBL3X, and ID1-ID2) used in the previous studies (16, 17), as several
domains are required for optimal VAR2CSA-mediated IE sequestration (42, 43). We did
not ﬁnd evidence that VAR2CSA-speciﬁc IgG is acquired any differently in Colombia
than in Africa. Furthermore, we found no indication to support the hypothesis that
exposure to P. vivax plays a role in these processes. Instead, our data show that
responses to recombinant antigens can be misleading if not checked carefully against
data obtained with the corresponding native antigens. Speciﬁcally, many Colombians
appear to possess IgG that reacts with recombinant PfEMP1 proteins expressed in
baculovirus-transfected insect cells. Whether this is also the case for other proteins not
related to malaria is not known. Importantly however, IgG reacting with a recombinant
protein expressed in this way (e.g., FV2BIC) does not necessarily react with a corre-
sponding protein expressed in another system (e.g., FV2CHO) or indeed with the native
protein that it represents (e.g., IT4VAR04). A possible explanation for the discrepancy
between FV2BIC IgG reactivity on the one hand and FV2CHO and IT4VAR04 reactivity on
the other is the marked differences in protein glycosylation among malaria parasites
(largely limited to the addition of glycosylphosphatidylinositol [GPI] anchors) (reviewed
in references 44 and 45), insect cells (simple carbohydrates only) (reviewed in reference
46), and CHO cells (complex, human-like carbohydrates) (reviewed in reference 47). IgG
reacting with recombinant antigens thus does not necessarily react (only) with the
antigen-speciﬁc protein core but may also recognize posttranslational modiﬁcations
that the antigen can share with many unrelated proteins produced in the same system.
In the present case, plasma IgG reactivity to FV2BIC among the Colombian donors
seemed to be largely of the latter kind, whereas FV6BIC reactivity (and FV2BIC reactivity
among the infected pregnant women) appeared to be a mix of both. We did not pursue
the nature of the epitopes in the baculovirus proteins recognized by IgG in plasma from
Colombia but not from Ghana, as this is likely to be a major undertaking that is well
beyond the scope of the present work. For the same reasons, we did not investigate
why these antibodies are common in Colombia while seemingly absent in Africa. It
might be worth noting that the highest IgG responses to insect cell-expressed recom-
binant antigens among Colombian donors were found among children, both here and
in the previous study. Exposure of Colombians to other pathogens or insects is another
potential explanation that was not investigated here.
FIG 6 Legend (Continued)
(Ebola virus-speciﬁc) human monoclonal IgG (EBL040), mouse polyclonal IgG, as well as the VAR2CSA-type PfEMP1-speciﬁc human
monoclonal antibody PAM1.4. (B, D, and F) IgG reactivities in human plasma pools from unexposed Colombians, infected pregnant
Colombians, exposed Ghanaian women, unexposed Danish adults, and preimmune rabbit serum are shown for comparison. Serial
2-fold dilution series are shown for all antibody reagents.
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Apart from advising the exertion of great care when interpreting ﬁndings using
recombinant proteins, we conclude from the present study that VAR2CSA-speciﬁc
immunity is acquired in the same way (i.e., by exposure to VAR2CSA-positive IEs during
pregnancy) in Colombia as in Africa. Furthermore, acquired immunity to VAR2CSA-type
PfEMP1 seems not to be inﬂuenced by exposure to P. vivax. The rationale for the
development of a VAR2CSA-based vaccine against placental malaria therefore stands
(41).
MATERIALS AND METHODS
Ethical approval. The original studies from which the samples used here were obtained were
approved by the Institutional Review Boards of the Malaria Vaccine and Drug Development Center
(MVDC) and the Centro Médico Imbanaco, Cali, Colombia; by the Institutional Review Board of the
Noguchi Memorial Institute for Medical Research, University of Ghana; and by the Regional Research
Ethics Committees, Capital Region of Denmark. The Colombian clinical trials were registered at Clinical-
Trials.gov (registration numbers NCT01585077 and NCT01082341). The present study was approved by
the Institutional Review Board at MVDC.
Study sites. Stored plasma samples from four previous studies involving ﬁve locations of Colombia
were used. Cali, Buenaventura, Tumaco, and Quibdó are located in the western and Paciﬁc regions, while
Tierralta is situated in the northwestern Caribbean region (Table 1) (48, 49). Cali (Department of Valle del
Cauca) is a city without malaria transmission. Buenaventura had an average annual parasite incidence
(API) of 3.1 in the period from 2011 to 2013. It has a population of predominantly African descent, with
indigenous and mestizo minorities; most malaria cases (75%) are caused by P. vivax. Tumaco (Depart-
ment of Nariño; API  10.3) has a highly predominant Afro-descendant population, and P. falciparum
dominates (85%) in this region. Quibdó (Department of Chocó; API  25) is also inhabited mainly by
Afro-descendants, and most malaria episodes (70%) are caused by P. falciparum. Tierralta (Department
of Córdoba; API 6.7) is inhabited mostly by mestizo populations, with a small Amerindian Emberá Katío
indigenous community; P. vivax dominates (85%) in this region.
Study samples. Several sets of samples were studied (Table 1). The ﬁrst set (set 1) (Table 1) was
obtained from a series of cross-sectional, active case detection studies carried out from 2011 to 2014 in
Buenaventura, Tumaco, and Tierralta (50). Samples from children (set 1a) and men (set 1b) who were
negative for malaria infection by quantitative PCR (qPCR) but with self-reported previous malaria
exposure were included.
The second set of samples (set 2) was obtained from a passive case detection study conducted from
2011 to 2013 at malaria points of care (15) and from 2014 to 2016 in hospitals (51) of Quibdó, Tumaco,
and Tierralta. Samples from children (set 2a) and men (set 2b) with acute P. vivax or P. falciparum malaria
as well as a set of plasma samples from pregnant women with P. vivax or P. falciparum malaria (51, 52)
(set 2c) were included.
The third set of samples (set 3) was collected from previously unexposed (set 3a) and semi-immune
men and women (set 3b) participating in a controlled human P. vivax malaria infection (PvCHMI) trial
carried out at MVDC in Cali. The unexposed (malaria antibody-negative) volunteers were from Cali,
whereas the semi-immune volunteers were from Buenaventura. Their previous malaria exposure was
conﬁrmed by clinical history and by the presence of P. vivax-speciﬁc antibodies. Samples collected at
enrollment, at patency (days 11 to 13), and 45 days after challenge (follow-up) were analyzed (25).
The fourth set of samples (set 4) was collected from previously unexposed adults during a clinical trial
in Cali to assess the safety and protective efﬁcacy of immunization with radiation-attenuated P. vivax
sporozoites (PvRAS) (27). Samples from Duffy-positive (Fy) (set 4a and set 4b) and Duffy-negative (Fy)
individuals (set 4c) were collected at enrollment, after seven immunizations, and after PvCHMI with
nonirradiated, P. vivax-infected mosquitoes.
Plasma samples from 32 nonpregnant women from Ghana with known reactivity to VAR2CSA-type
PfEMP1 (18) (set 5) and from 11 Danish adults without malaria exposure (set 6) were included as positive
and negative controls, respectively.
Recombinant parasite proteins. The entire ectodomains of the VAR2CSA-type PfEMP1 protein
IT4VAR04 (FV2BIC; GenBank accession number GU249598) and of the non-VAR2CSA-type PfEMP1 protein
HB3VAR06 (FV6BIC; GenBank accession number KP_203835) were produced in baculovirus-transfected Sf9
insect cells, as described previously (20, 42). A third recombinant protein (FV2CHO), identical to FV2BIC but
expressed in suspension-adapted CHO cells (ExpiCHO; ThermoFisher Scientiﬁc) according to the manu-
facturer’s instructions, was also used. In brief, a full-length construct with a C-terminal histidine tag was
cloned into the vector pcDNA3.4 and used to transfect ExpiCHO-S cells. Glycosylation sites were not
removed. Secreted recombinant proteins were puriﬁed from the supernatants by using Ni2 metal
chelation agarose (HisTrap HP columns; GE Healthcare).
Recombinant P. vivax Duffy binding protein region II (PvDBP), produced in Escherichia coli, was a kind
gift from John H. Adams (University of South Florida) (28).
Antibody reagents. For the in vitro selection of particular PfEMP1 proteins expressed on the IE
surface (see below), we used human monoclonal antibody PAM1.4, which is speciﬁc for a conformational
epitope in several VAR2CSA-type PfEMP1 proteins, including IT4VAR04 (53). We used a rabbit antiserum
raised against FV6BIC (20) to select for IE surface expression of the non-VAR2CSA-type PfEMP1 protein
HB3VAR06.
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PvDBP-speciﬁc mouse monoclonal IgG1 antibody 3D10 (28) was a kind gift from John H. Adams
(University of South Florida). The human monoclonal IgG1 antibody DBL10, also speciﬁc for PvDBP (our
unpublished data); the human monoclonal EBL040 IgG1 antibody, speciﬁc for an Ebola virus antigen
(used here as a control reagent); as well as rabbit anti-PvDBP serum (30) were kind gifts from Thomas
Rawlinson and Simon Draper (University of Oxford, UK).
Assessment of the IgG antibody response to recombinant proteins. IgG reactivity against FV2BIC,
FV2CHO, FV6BIC, and PvDBP was measured in duplicate by an ELISA as described previously (18, 28, 54).
Brieﬂy, 96-well ﬂat-bottom microtiter plates (Nunc MaxiSorp) were coated with recombinant protein in
Dulbecco’s phosphate-buffered saline (Lonza). After blocking and washing, human plasma samples
(1:400), human and mouse monoclonal antibodies (0.08 to 10 g/ml), or rabbit serum (1:20 to 1:2,560)
was added, followed by horseradish peroxidase-conjugated rabbit anti-human IgG (1:3,000; Dako), goat
anti-mouse IgG (1:1,000; ThermoFisher), or goat anti-rabbit IgG (1:3,000; Dako). Bound antibodies were
detected by adding tetramethylbenzidine (TMB PLUS2; Eco-Tek), and the reaction was stopped by the
addition of 0.2 M H2SO4 to the mixture. The optical density (OD) was read at 450 nm, and the speciﬁc
antibody levels were calculated in arbitrary units (AU), as described previously (18). Negative cutoff
values were calculated as the mean AU values plus 2 standard deviations (SD) obtained with the Danish
control samples (set 6) (Table 1).
Depletion of IgG reactivity to recombinant proteins. Pooled plasma samples from Colombian
pregnant women (set 2c; n  56) and adults without previous malaria exposure (sets 3a, 4a, and 4b;
n  22 enrollment samples), malaria-exposed nonpregnant women from Ghana (set 5; n  32), and
unexposed Danish adults (set 6; n  11) were tested in three sequential ELISAs. In the ﬁrst ELISA,
levels of IgG speciﬁc for FV2BIC, FV2CHO, and FV6BIC were measured. After incubation (1 h), the
depleted pools were transferred directly to new plates coated with the same protein used in the ﬁrst
ELISA. After incubation (1 h), the further depleted pools were transferred to FV2BIC-coated plates and
once again incubated as described above. Further processing was performed as described above.
For these experiments, the data were normalized by dividing the sample OD by the OD for the
corresponding negative control (fold over control).
Malaria parasite culture and selection in vitro. P. falciparum clones IT4/FCR3 and HB3 were
maintained in serum-free medium as described previously (55). Erythrocytes infected by late-stage
IT4/FCR3 parasites were selected for surface expression of IT4VAR04 by immunomagnetic selection using
protein A-coupled DynaBeads coated with PAM1.4, as described previously (56). A similar approach was
used to select HB3-IEs for surface expression of HB3VAR06, using an HB3VAR06-speciﬁc rabbit antiserum
(20). Transcription of the relevant var genes and IE surface expression of the corresponding PfEMP1
protein were monitored by quantitative real-time PCR (57) and ﬂow cytometry (56), respectively. The
genotypic identity of the parasites (58) and the absence of Mycoplasma contamination determined by
using the MycoAlert mycoplasma detection kit (Lonza) were veriﬁed regularly.
Antibody reactivity with the surface of P. falciparum-infected erythrocytes. Plasma IgG reactivity
against IEs expressing IT4VAR04 or HB3VAR06 was analyzed by ﬂow cytometry, as described previously
(56), using a Beckman Coulter FC500 ﬂow cytometer for data acquisition and FlowLogic software (Inivai
Technologies, Australia) for list mode data analysis. IgG binding to IEs was quantiﬁed as the relative
median ﬂuorescence intensity (rMFI) using the equation 100 	 [(MFIsample  MFIblank)/(MFIpositive control 
MFIblank)]. Negative cutoff values were calculated as the mean of rMFI values plus 2 SD obtained with the
Danish control samples (set 6).
Statistical analysis. Data were analyzed by using GraphPad Prism version 6.0 (GraphPad Software,
San Diego, CA, USA). All experiments reported here were repeated at least twice, with similar results. The
Mann-Whitney U or Kruskal-Wallis test followed by Dunn’s multiple-comparison test was used to
compare two or more than two groups, respectively. Spearman’s rank correlation (rs) was used to assess
the correlation between numeric variables. A chi-square test was used to compare differences in
proportions. P values of 0.05 were considered statistically signiﬁcant.
SUPPLEMENTAL MATERIAL
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